ClinicalTrials.gg
TerminatedNCT05720052Updated Jul 18, 2024

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

A Phase 1/2 interventional study of MS-553 in Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), sponsored by MingSight Pharmaceuticals, Inc. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-18.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by MingSight Pharmaceuticals, Inc · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study is terminated due to major protocol revisions.
Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except malignant lymphoblastic lymphoma (LBL) and Burkitt lymphoma. After the RP2D is identified, Phase II of subjects with relapsed or refractory mantle cell lymphoma who previously received ≥ 2 and ≤ 4 different chemotherapy and/or targeted drug therapy will be enrolled.

02

Conditions studied

  • Relapsed or Refractory B-cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Marginal Zone Lymphoma (MZL)
03

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,868 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 355 are open to participants now.

This study's enrollment of 8 is below the median of 45 across 1,497 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

MingSight Pharmaceuticals, Inc is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients in Phase I study will be enrolled with or relapsed B-cell non-Hodgkin lymphoma.
    1. Patients enrolled in the phase I study failed two or more regimens; Patients with mantle cell lymphoma should also be patients with or failure of BTK inhibitor therapy.
    1. (ECOG) performance status score is 0\~2.
    1. Have ≥ 3 months.
    1. Major organ functions meet the following criteria:

      • In the absence of growth factor support therapy or blood transfusion in the last 14 days: ≥1.5×109/L, ≥80 g/L, ≥75×109/L (no platelet transfusion within 14 days); if accompanied with bone marrow invasion, neutrophils ≥1.0×109/L, platelets ≥50×109/L.
      • Biochemistry: Total ≤1.5× or ≤3.0×ULN in Gilbert's syndrome, or ALT ≤2.5×ULN, serum creatinine ≤1.5×ULN or calculated ≥60 mL/min (Cockcroft-Gault formula).
      • Coagulation function: (INR) and activated partial thrombin time ≤ 1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

    1. Present or prior history of other (except cured carcinoma in situ of cervix and basal cell carcinoma of skin), unless there is radical treatment and no evidence of recurrence or within the last 2 years.
    1. Lymphomas involved the central nervous system.
    1. Patients with history of organ transplantation or hematopoietic stem cell transplantation; patients who have received autologous hematopoietic stem cell transplantation or CAR-T treatment within the past 3 months,
    1. Patients who are suitable and ready for autologous stem cell transplantation.
    1. History of eye surgery or trauma within 3 months before the screening visit, history of serious eye infection or the most recent eye surgery within 4 weeks before the screening visit.
    1. Has had active and uncontrolled hemocytopenia, including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura.
    1. Has had uncontrolled or significant cardiovascular diseases, including:
    1. Women who are lactating or pregnant.
    1. Women of who do not agree to have two pregnancy tests prior to first dose (at least one of tests is serum pregnancy test) and the test result shall be negative.
    1. Male patients who do not agree to the measures.
    1. Any conditions that in the opinion of the investigator considers inappropriate to participate in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Single arm

    dose exploration

    Drug: MS-553

Interventions

  • DrugMS-553

    MS-553 oral tablet BID x 28-days

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT)

    Time frame: First cycle (28 days)

  2. Incidence and severity of adverse events

    Time frame: up to 24 months

  3. To determine the MTD and RP2D of oral MS-553 in patients with BCL

    Time frame: about 8 months

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: up to 24 months

  2. Duration of response (DOR)

    Time frame: up to 24 months

  3. progression-free survival (PFS)

    Time frame: up to 24 months

  4. overall survival (OS)

    Time frame: up to 24 months

  5. time to progression (TTR)

    Time frame: up to 24 months

  6. disease control rate (DCR)

    Time frame: up to 24 months

  7. Pharmacokinetics parameters: Cmax

    Time frame: within the first 2 cycles (56 days)

  8. Pharmacokinetics parameters: Tmax

    Time frame: within the first 2 cycles (56 days)

  9. Pharmacokinetics parameters: T1/2

    Time frame: within the first 2 cycles (56 days)

  10. Pharmacokinetics parameters: AUC0-12

    Time frame: within the first 2 cycles (56 days)

  11. Pharmacokinetics parameters: CL/F

    Time frame: within the first 2 cycles (56 days)

07

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05720052
Lead sponsor
MingSight Pharmaceuticals, Inc
Collaborators
Shenzhen MingSight Relin Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Feb 6, 2023
Primary completion
Nov 28, 2023
Completion
Nov 28, 2023
Last update
Jul 18, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PKC-beta Inhibitor MS-553

Start the discussion